Anti-Human CD274 Recombinant Antibody(Durvalumab)

Product Information

Catalog Number	YR1356
Product Name	Anti-Human CD274 Recombinant Antibody(Durvalumab)
Molecular Name	Durvalumab
Alias	Anti-CD274 Recombinant Antibody, Research Grade Durvalumab
CAS Number	1428935-60-7
Target	CD274[Homo sapiens]
Isotype	IgG1 Kappa
Clonity	Monoclonal
Source	CHO Cells
Size	1mg, 5mg
Concentration	1mg/ml
Purity	>95% as determined by SDS-PAGE
Applications	ELISA, IHC, FCM, IP, IF, Inhib, FuncS
Buffer	PBS, pH7.5
Background	Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is known as a checkpoint inhibitor drug.
Storage	It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles.
Note	This product is for research use only.

Cat#	Product Name	Species	Host	Applications	Size	Price